Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000173158 | SCV000224250 | uncertain significance | not provided | 2017-10-19 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001242007 | SCV001415067 | likely benign | Niemann-Pick disease, type B; Niemann-Pick disease, type A | 2025-01-23 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000173158 | SCV003822010 | uncertain significance | not provided | 2019-04-03 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003258676 | SCV003945069 | uncertain significance | Inborn genetic diseases | 2023-03-21 | criteria provided, single submitter | clinical testing | The c.103C>G (p.L35V) alteration is located in exon 1 (coding exon 1) of the SMPD1 gene. This alteration results from a C to G substitution at nucleotide position 103, causing the leucine (L) at amino acid position 35 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004742305 | SCV005354025 | uncertain significance | SMPD1-related disorder | 2024-04-11 | no assertion criteria provided | clinical testing | The SMPD1 c.103C>G variant is predicted to result in the amino acid substitution p.Leu35Val. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.021% of alleles in individuals of Latino descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |